Can low bioavailable testosterone mean lower muscle anabolic capacity and a lower red blood cell count?

At age 71, lower bioavailable testosterone can be relevant to both muscle anabolism and red-cell physiology, but these relationships have different evidentiary strength. The erythropoietic link is clinically well established; “anabolic repair reserve” is a useful mechanistic concept rather than a defined clinical diagnosis.

Clinical evidence

• Testosterone supports skeletal-muscle anabolism. In older men, 4 weeks of treatment increased muscle fractional synthetic rate, strength, and intramuscular IGF-1 mRNA; 6 weeks combined with resistance exercise increased synthesis and net protein accretion. Conversely, experimental hypogonadism reduced a whole-body protein-synthesis index by 13%.
• Lower free/bioavailable testosterone is associated with sarcopenia, frailty, weaker grip, slower gait, and muscle loss in cohorts, although longitudinal results are not fully consistent. Thus, it can align with reduced anabolic capacity, but does not demonstrate a measurable deficit in a distinct “repair reserve.”
• The red-cell association is stronger. In older men, low bioavailable/free testosterone independently tracks with lower hemoglobin and anemia; in diabetes it was associated with approximately doubled adjusted odds of anemia. Testosterone increased hemoglobin by 0.58 g/dL versus placebo in older men with unexplained anemia, and by about 0.9 g/dL over 36 months in hypogonadal older men.

Mechanisms and safety

• Androgen signaling may increase muscle protein synthesis through androgen-receptor and IGF-1/PI3K–Akt–mTORC1-related signaling, while longer-term lean-tissue accretion may depend substantially on reduced protein breakdown.
• Testosterone stimulates erythropoiesis by transiently altering erythropoietin feedback and suppressing hepcidin, increasing ferroportin-mediated iron availability; marrow progenitor effects may also contribute.
• Iron deficiency, kidney disease, inflammation, bleeding, nutritional status, and activity can independently affect these outcomes. Testosterone can cause erythrocytosis, requiring hemoglobin/hematocrit monitoring.

Bottom line

• Low bioavailable testosterone can credibly accompany lower red-cell measures and may signal lower muscle anabolic capacity, but it neither defines “repair reserve” nor substitutes for evaluation of other causes of anemia or functional decline.